The World's Only Transdermal Dopamin Agonist, Neupro® Patch, Approved in Japan for Both Parkinson's Disease and Restless Legs Syndrome The only transdermal dopamine agonist*1 system, which helps ...

Latest safety and efficacy results for rotigotine in the treatment of moderate to severe restless legs syndrome presented at major North American neurology congress Brussels (Belgium), 13 April 2010, ...

BRUSSELS, July 28 UCB today announced the results of a 6-month, randomized, double-blind, placebo-controlled clinical study, published in the journal Movement Disorders, showing that Neupro® ...

UCB will need to resolve issues concerning crystal formation before regulators in the USA approve the Belgian firm’s Neupro patch for Parkinson’s disease and restless legs syndrome. UCB will need to ...

Rotigotine 2 mg/24 hours, 4 mg/24 hours, 6 mg/24 hours; transdermal patch; contains sulfites. Neupro is a transdermal patch containing rotigotine, a D3/D2/D1 dopamine agonist. The mechanism of action ...

BRUSSELS and ATLANTA, July 16, 2012 /PRNewswire/ -- UCB announced today that Neupro ® (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro ® was approved by the U.S Food and ...

A new treatment for Parkinson's disease, in the form of a patch, promises an end to "off time" - that period between doses when tremors return It is the first time treatment for Parkinson's has come ...

Neupro (rotigotine transdermal system, from UCB and Schwarz Pharma) patches are being recalled due to the formation of rotigotine crystals in the patches. When the drug crystallizes, less drug is ...

ATLANTA — UCB has launched a new drug for treating Parkinson's disease and restless legs syndrome, the company said Monday. The Belgian drug maker announced the launch of Neupro (rotigotine) ...

Atlanta, April 13th, 2010 – New data presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada, showed that patients with moderate to severe Restless Legs Syndrome (RLS) ...